Benign Hematology Service
Infectious Disease
1
| Disease Status and/or Stage | Compromised GI function and at high risk for invasive fungal infection |
|---|---|
| Protocol Title | A Phase 4 study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) among Patients with Compromised Gastrointestinal Function at a High Risk for Invasive Fungal Infection |
| PI | David Helfgott, MD |
| Contact | Tania Curcio, RN 212-746-2571 |
| Key Eligibility | Patients at least 18 years old at high risk of poor enteral medication absorption, based on the effects of cytotoxic chemotherapy, including but not limited to, mucositis, nausea, vomiting, and diarrhea at baseline. Patients must be at high risk for invasive fungal infection. |
| Treatment Overview |
All subjects will receive Posaconazole 200 mg three times daily (TID) for Days 1 to 8. On Day 8, subjects will be randomized to one of three dosing regimens to commence on Days 9 to 15: |
| Last updated: July 30, 2008 |  |
